UPDATED 15:49 PT – Monday, October 26, 2020
The US pharmaceutical giant Pfizer has included more than 42,000 people in the second phase 2 trial of its potential COVID-19 vaccine. The company also said more than 35,000 participants received a second dose of vaccination.
PFIZER INC – PHASE 2/3 COVID-19 VACCINE STUDY RECORD 42 113 PARTICIPANTS AND 35 771 PARTICIPANTS RECEIVED THE SECOND VACCINATION
– First Squawk (@FirstSquawk) October 26, 2020
The pharmaceutical company is one of the leaders in the coronavirus vaccine race. President Trump also mentioned the company during the last presidential debate.
“Pfizer is doing very well and we have many others,” he said. “And then we have others that we are working on closely with other countries, especially Europe.”
The world is waiting for a safe and effective vaccine # COVID19. Today, our chairman and CEO wrote an open letter to help people understand the criteria we must meet and the expected timelines for our vaccine research program. https://t.co/RlhDYq4vK0
– Pfizer Inc. (@pfizer) October 16, 2020
The researchers hope the test results will be available by November, and if so, they will be sent to the FDA for a review process that could take up to four weeks.